Glenmark get MHRA nod for antimalarial tablet
DSIJ Intelligence / 04 Jul 2017
On July 4, 2017, Glenmark Pharmaceuticals Limited get the medicines and healthcare products Regulatory Agency (MHRA) approval for an antimalarial tablet which will be sold under the brand name Maloff Protect.
On July 4, 2017, a global pharmaceutical company, Glenmark Pharmaceuticals Limited who is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs) get the medicines and healthcare products Regulatory Agency (MHRA) approval for an antimalarial tablet which will be sold under the brand name Maloff Protect.
Maloff Protect is a medicine which is used to prevent malaria infection in adults. Atovaquone and proguanil are the active ingredients in the tablet. Both of these are in a class of drugs called biguanides which is used to prevent and treat malaria This tablet will be available through pharmacies without prescription.
In addition to this approval, Glenmark UK continues to identify and explore both internal as well as external development partnerships to supplement and accelerate the growth of its existing opportunities and future portfolio.
On July 3,2017, Glenmark was trading at Rs 642.65, up by 0.52 per cent on BSE at 10:04 hours. It opened at Rs 644.90, while on Monday it closed at Rs 639.35. Glenmark intraday high and low are Rs 646.05 and 641.10 respectively. S&P BSE Healthcare was trading at 14247.23 levels, up by 0.14 per cent.